News

A doctor shares 7 steps he'll review to decide when and where it's safe to go out and about

William Petri
By William Petri
June 14, 2020

As we return to some degree of normalcy after weeks of social distancing, we all need a plan. As an immunologist, I’ve given this a lot of thought personally and professionally.

When I venture out, I am first going to check the number of new COVID-19 infections in my community. In Virginia, for example, as of May 16, some health districts had 200 new daily cases and others fewer than 10. I am going to be less risk-averse when new cases fall to near zero.

Second, I will assess my risk for severe infection and the risk for severe infection for those I will be visiting. The CDC defines these risk factors as being over age 65 or having serious underlying medical conditions, which include chronic lung disease, moderate to severe asthma, serious heart conditions, immunocompromise, severe obesity (body mass index over 40), diabetes, kidney disease requiring dialysis, liver disease or living in a nursing home or long-term care facility. If I have one of these risk factors, or am visiting someone with one of these risk factors, I am going to be extra-cautious.

Third, I will draw from knowledge about how COVID-19 is transmitted. Airborne transmission and fomites, or contaminated surfaces such as doorknobs, are both means of infection. The SARS-CoV-2 virus that causes COVID-19 is stable in airborne droplets, or aerosols, for hours and on the surface of cardboard for a day and plastics for two days. A study in the New England Journal of Medicine, for example, showed that half of nursing home patients who had COVID-19 were without symptoms at the time of diagnosis, by nasal swab PCR test for the virus, and yet infectious to others. Normal speech generates oral fluid droplets which are potentially infectious but are captured by a cloth face mask, preventing transmission to others.

I am going to wear a mask to help prevent my giving the infection to others, avoid touching surfaces such as handrails, try not to touch my eyes or nose or mouth with my hands and wash my hands frequently.

I am going to try to stay outdoors, where the risk of infection from aerosols is less, and if indoors stay six feet distant from others and limit my time there.

I am going to assess my risk for infecting others. If I have a fever, cough or other flu-like symptoms, such as muscle aches or tiredness, I am not going to venture out and risk exposing others to COVID-19. Even if healthy, I am going to wear a mask when out so that I can protect others if I am unknowingly infected but pre-symptomatic.

While it is tempting to resume normal activities, I have to remember – and I hope you will, too – that my individual behavior affects not only my health, but also yours.The Conversation

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Image credit: Danielle Rice/Unsplash

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
William Petri
William Petri

William Petri is a professor of  medicine and microbiology at the University of Virginia who specializes in infectious diseases.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Unraveling the language of histones
Profile

Unraveling the language of histones

Nov. 20, 2025

Philip Cole presented his research on how posttranslational modifications to histones are involved in gene expression and how these modifications could be therapeutically targeted to treat diseases like cancer.

How Alixorexton could transform narcolepsy treatment
News

How Alixorexton could transform narcolepsy treatment

Nov. 18, 2025

A new investigational drug, alixorexton, targets the brain’s orexin system to restore wakefulness in people with narcolepsy type 1. Alkermes chemist Brian Raymer shares how molecular modeling turned a lab idea into a promising phase 3 therapy.

Phosphatases and pupils: A dual legacy
Profile

Phosphatases and pupils: A dual legacy

Nov. 13, 2025

Yale professor Anton Bennett explores how protein tyrosine phosphatases shape disease, while building a legacy of mentorship that expands opportunity and fuels discovery in biochemistry and molecular biology.

Extracellular vesicles offer clues to cattle reproduction
Journal News

Extracellular vesicles offer clues to cattle reproduction

Nov. 11, 2025

Extracellular vesicles from pregnant cattle support embryo development better than laboratory models, highlighting their potential to improve reproductive efficiency in bovine embryo cultures. Read more about this recent MCP paper.

Proteomics reveals protein shifts in diabetic eye disease
Journal News

Proteomics reveals protein shifts in diabetic eye disease

Nov. 11, 2025

Using proteomics, researchers identified protein changes in eye fluid that mark diabetic retinopathy progression and may serve as biomarkers for vision-threatening complications. Read more about this recent MCP paper.

Protein modifications drive lung cancer resistance
Journal News

Protein modifications drive lung cancer resistance

Nov. 6, 2025

New assay enriches protein modifications in a single process, enabling detection of key changes in drug-resistant lung cancer cells that may guide future therapies.